Chimerix
serious adverse events | Chimerix
Company
Deck Type
Sector
Industry
Deck date
November 2021
Slide
12 of 32
Related slides by other companies
DICE Therapeutics
Investor Presentation
March 2023
demonstrated a favorable safety and tolerability profile | DICE Therapeutics
BenevolentAI
Investor Presentation
September 2024
| BenevolentAI
NeuroSense Therapeutics
Investor Presentation
January 2024
achieved primary with a safety and tolerability profile comparable to placebo phase study results | NeuroSense Therapeutics
Compass Therapeutics
Investor Presentation
May 2022
safety data treatment related grade adverse events | Compass Therapeutics
Other recent decks by Chimerix
See all presentations (6 decks)
Investor Presentation
August 2023
Investor Presentation
May 2023
Investor Presentation
March 2023
Results
March 2022
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights